The preference for conservative P2Y12 inhibitors in this population may explain the low bleeding event rates observed in our cohort.42Nonetheless, our findings are consistent with previous studies in cardiovascular disease populations, reinforcing the importance of personalized treatment strategies in these patients. This evidence concerns the gene P2RY12 and cardiovascular disorder.